While these results highlight the potential utility of GNAS and other genetic markers to serve in clinical decision-making for IPMN, prospective clinical studies are required in order to validate these current observations. The gene discussed is GNAS; the disease is pancreatic intraductal papillary-mucinous neoplasm.